Heidari Zahra, Abdani Mahdi, Mansournia Mohammad Ali
MD, Department of Endocrinology and Metabolism, Zahedan University of Medical Sciences, Zahedan, IR Iran.
MD, MPH, PhD, Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran.
Int J Endocrinol Metab. 2017 Oct 25;16(1):e14545. doi: 10.5812/ijem.14545. eCollection 2018 Jan.
In the recent years, thyroid cancer incidence has increased worldwide. It has been questioned whether factors, such as insulin resistance, are involved in this rise. The main aim of this study was to examine the association between insulin resistance and differentiated thyroid cancer.
This case-control study was performed on 30 newly diagnosed patients with differentiated thyroid cancer and 30 healthy controls. Thirty euthyroid patients recently diagnosed with differentiated thyroid cancer, based on the fine needle aspiration cytology, were examined for insulin resistance before thyroidectomy in the euthyroid state. For each patient in the case group, one healthy euthyroid individual without thyroid nodule from general population was matched based on gender, age (± 1 year), and body mass index (BMI) (± 1). Thyroid function test, thyroid antibodies, serum glucose, serum insulin, and thyroid ultrasonography was performed for all participants. Insulin resistance was defined based on homeostasis model assessment of insulin resistance (HOMA-IR) to be more than 2.5.
In the patient group, 24 (80%) cases were female and 6 (20%) were male. Insulin resistance was more prevalent in the case group than the control group (43.3% versus 13.3%). Insulin sensitivity index was lower in the case group than in the control group (50 and 81, respectively). There was a significant positive association between serum HOMA-IR levels and differentiated thyroid cancer (OR: 2.43 for 1 unit increase in HOMA-IR, 95% CI: 1.35 - 5.51; P = 0.001). Insulin resistance was significantly associated with differentiated thyroid cancer (OR: 4, 95 % CI: 1.27 - 17.6; P = 0.016).
There was a significant association between insulin resistance and differentiated thyroid carcinoma. More research with a larger sample size and prospective design are needed to determine the role of this factor in the development of differentiated thyroid cancers.
近年来,全球甲状腺癌发病率呈上升趋势。胰岛素抵抗等因素是否与这一上升有关一直受到质疑。本研究的主要目的是探讨胰岛素抵抗与分化型甲状腺癌之间的关联。
本病例对照研究选取了30例新诊断的分化型甲状腺癌患者和30例健康对照者。30例根据细针穿刺细胞学诊断为分化型甲状腺癌的甲状腺功能正常患者,在甲状腺功能正常状态下甲状腺切除术前检查胰岛素抵抗情况。对于病例组中的每一位患者,从普通人群中匹配一名无甲状腺结节的健康甲状腺功能正常个体,匹配因素包括性别、年龄(±1岁)和体重指数(BMI)(±1)。对所有参与者进行甲状腺功能检查、甲状腺抗体检测、血糖、胰岛素检测以及甲状腺超声检查。根据胰岛素抵抗稳态模型评估(HOMA-IR)将胰岛素抵抗定义为大于2.5。
患者组中,女性24例(80%),男性6例(20%)。病例组中胰岛素抵抗的发生率高于对照组(43.3%对13.3%)。病例组的胰岛素敏感指数低于对照组(分别为50和81)。血清HOMA-IR水平与分化型甲状腺癌之间存在显著正相关(HOMA-IR每增加1个单位,OR:2.43,95%CI:1.35 - 5.51;P = 0.001)。胰岛素抵抗与分化型甲状腺癌显著相关(OR:4,95%CI:1.27 - 17.6;P = 0.016)。
胰岛素抵抗与分化型甲状腺癌之间存在显著关联。需要开展更大样本量和前瞻性设计的更多研究,以确定该因素在分化型甲状腺癌发生发展中的作用。